BACKGROUND: The incidence of cytomegalovirus (CMV) syndrome/disease after adult
solid organ transplantation in the era effective antiviral therapy has not been fully assessed …

BACKGROUND: Cytomegalovirus (CMV) is a significant infectious agent after liver
transplantation. To prevent CMV, most centres use prophylaxis for high-risk CMV …

Objectives Prophylaxis (P) or pre‐emptive strategy (PS) in high‐risk liver transplant
recipients (LTRs) are either recommended. We compared the results of each strategy …

Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …

Background. Antiviral prophylaxis has been shown to decrease the incidence of
cytomegalovirus (CMV) disease in organ transplant recipients, but whether CMV disease …

Context Cytomegalovirus (CMV) is an opportunistic infection that causes profound morbidity
and mortality after orthotopic liver transplant (OLT). The CMV immunoglobulin G …

Background. Cytomegalovirus (CMV) is a significant cause of morbidity, mortality, and cost
in solid organ transplant recipients. This study was conducted to measure both the clinical …

INTRODUCTION: Cytomegalovirus (CMV) infection is a significant cause of morbidity and
mortality among heart transplant (HT) patients. Various prophylactic and preemptive …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

Purpose: We evaluated the efficacy and safety of the current cytomegalovirus (CMV)
prophylaxis regimen used at Virginia Mason Medical Center in Seattle. Methods: A single …